Country

Clinical trials in India

Active obesity and GLP-1 studies with at least one location in India.

28active studies

17recruiting now

40countries represented

157largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

Diabetes Mellitus, Type 2, Diabetes MelletusCondition

OrforglipronTreatment

India, Saudi Arabia40 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07613307See eligibility →

Recruiting nowPhase 3

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Type 2 DiabetesCondition

Placebo, SurvodutideTreatment

Australia, Canada121 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07754461See eligibility →

Recruiting nowPhase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, SemaglutideTreatment

Australia, Austria121 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07253285See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowPhase 4

Fibrosis Lessens After Metabolic Surgery

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver DiseaseCondition

Metabolic surgery, Incretin-Based TherapyTreatment

Brazil, Canada22 locations

The Cleveland ClinicSponsor

Updated 2026-07-31 · NCT06374875See eligibility →

Recruiting nowNot applicable

Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome

Obesity & Overweight, Metabolic SyndromeCondition

Kodo Millet Porridge BeverageTreatment

India1 locations

JSS MEDICAL COLLEGE, JSS ACADEMY OF HIGHER EDUCATION AND RESEARCHSponsor

Updated 2026-07-14 · NCT07703371See eligibility →

Recruiting nowPhase 3

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China80 locations

Novo Nordisk A/SSponsor

Updated 2026-07-13 · NCT07571005See eligibility →

Recruiting nowPhase 4

Evaluation of Propofol Dosing Based on Total Body Weight Using Closes-loop Anaesthesia Delivery System

Obesity, Morbid, AnesthesiaCondition

Propofol, PropofolTreatment

India1 locations

Sir Ganga Ram HospitalSponsor

Updated 2026-04-27 · NCT05305313See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

Type II Diabetes MellitusCondition

GL0034 Dose Level 1, GL0034 Dose Level 2Treatment

India, United States21 locations

Sun Pharmaceutical Industries LimitedSponsor

Updated 2026-03-18 · NCT07282743See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Chronic Kidney DiseaseCondition

NNC0519-0130, PlaceboTreatment

Argentina, Australia147 locations

Novo Nordisk A/SSponsor

Updated 2026-03-11 · NCT06717698See eligibility →

Recruiting nowNot applicable

Comorbidities Resolution After MGB Surgery and Change in Body Composition

Morbid Obesity, Type2diabetesCondition

Mini gastric bypass surgeryTreatment

India1 locations

All India Institute of Medical Sciences, BhubaneswarSponsor

Updated 2026-02-18 · NCT06015620See eligibility →

Recruiting nowNot applicable

Effect of Indianized Version of Mediterranean Diet vs. Low Fat Diet on Hepatic Steatosis in Overweight Children and Adolescent With MASLD

Metabolic Dysfunction-Associated Steatotic Liver DiseaseCondition

Indianized version of Mediterranean Diet, Low Fat DietTreatment

India1 locations

Institute of Liver and Biliary Sciences, IndiaSponsor

Updated 2026-01-06 · NCT06768216See eligibility →

Recruiting nowNot applicable

Effect of Weight Loss From ESG Plus Lifestyle Changes vs. Lifestyle Changes Alone in Sleep Apnea Patients

OSA - Obstructive Sleep ApneaCondition

Endoscopic Sleeve Gastropathy, Lifestyle Modification aloneTreatment

India1 locations

Asian Institute of Gastroenterology, IndiaSponsor

Updated 2025-12-19 · NCT07082608See eligibility →

Recruiting nowNot applicable

Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus

Liver Transplant; Complications, Diabete MellitusCondition

Semaglutide PillTreatment

India1 locations

Medanta, The Medicity, IndiaSponsor

Updated 2025-06-13 · NCT06060392See eligibility →

Recruiting nowNot applicable

Conventional Vs Tailored Limb Lengths in Laparoscopic Roux-en Y Gastric Bypass Surgery

Obesity, Metabolic DiseaseCondition

Laparoscopic Roux-en Y Gastric bypass (RYGB)- Conventional approach, Laparoscopic Roux-en Y Gastric bypass (RYGB)- Tailored approachTreatment

India1 locations

GEM Hospital & Research CenterSponsor

Updated 2025-01-03 · NCT06756789See eligibility →

Opening soonPhase 3

AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

Obesity, OverweightCondition

Zenagamtide, Placebo ( matched to Zenagamtide)Treatment

India, Japan44 locations

Novo Nordisk A/SSponsor

Updated 2026-08-24 · NCT07668401See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

Orforglipron, DulaglutideTreatment

Belgium, Brazil71 locations

Eli Lilly and CompanySponsor

Updated 2026-08-19 · NCT07668336See eligibility →

Opening soonPhase 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

Argentina, Brazil56 locations

Novo Nordisk A/SSponsor

Updated 2026-05-28 · NCT07282613See eligibility →

Opening soonNot applicable

Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.

Chronic Kidney Diseases, MAFLDCondition

Semaglutide Oral Tablet, PlaceboTreatment

India1 locations

Institute of Liver and Biliary Sciences, IndiaSponsor

Updated 2026-02-05 · NCT07391267See eligibility →

Opening soonNot applicable

Building Healthy Food Environment in Schools: Evaluating Co-created Interventions in Low Resource Settings. #BetterNutrition4Adolescent

Overweight Adolescents, UnderweightCondition

Multicomponent school nutrition intervention, Usual nutrition programTreatment

India, Nepal2 locations

Norwegian University of Science and TechnologySponsor

Updated 2026-01-12 · NCT07332676See eligibility →

Invitation onlyNot applicable

Body Fat Reduction and Weight Management

Obesity & OverweightCondition

Dietary Supplement, Placebo ControlTreatment

India1 locations

Bioagile Therapeutics Pvt. Ltd.Sponsor

Updated 2026-01-30 · NCT07378033See eligibility →

Active, not recruitingPhase 4

A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

Diabetes Mellitus, Type 2, ObesityCondition

TirzepatideTreatment

India21 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT07438444See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Brazil, China138 locations

Eli Lilly and CompanySponsor

Updated 2026-08-14 · NCT05869903See eligibility →

Active, not recruitingPhase 3

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

ObesityCondition

Liraglutide, PlaceboTreatment

Belgium, India32 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT04775082See eligibility →

Active, not recruitingNot applicable

Dietary Intake, Sarcopenic Obesity, and Other Treatment-Related Outcomes in Indian Children With Acute Lymphoblastic Leukemia

Sarcopenic ObesityCondition

Vegetarian DietTreatment

India1 locations

Columbia UniversitySponsor

Updated 2026-01-08 · NCT03974893See eligibility →

Active, not recruitingNot applicable

Effect of Herbal Compositions on Body Weight, Body Composition and Metabolic Health in Overweight Subjects

Healthy ParticipantsCondition

CL19183, CL24212Treatment

India1 locations

ApexCPG LLCSponsor

Updated 2025-12-01 · NCT07083947See eligibility →

Related countries

United States1,107 China326 Canada158 France110 Spain98 Germany95

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.